Treasurer of the State of North Carolina reduced its stake in shares of Enovis Co. (NYSE:ENOV – Get Rating) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,972 shares of the company’s stock after selling 320 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Enovis were worth $1,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of ENOV. Godsey & Gibb Inc. purchased a new position in shares of Enovis in the fourth quarter worth $64,000. Seven Eight Capital LP purchased a new position in shares of Enovis in the third quarter worth $210,000. UBS Group AG lifted its holdings in shares of Enovis by 102.6% in the fourth quarter. UBS Group AG now owns 4,110 shares of the company’s stock worth $220,000 after buying an additional 2,081 shares in the last quarter. Quantamental Technologies LLC purchased a new position in shares of Enovis in the third quarter worth $221,000. Finally, Bank of Montreal Can purchased a new position in shares of Enovis in the fourth quarter worth $227,000. Hedge funds and other institutional investors own 96.73% of the company’s stock.
Insider Buying and Selling at Enovis
In other Enovis news, SVP Patricia A. Lang sold 545 shares of the business’s stock in a transaction on Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total transaction of $33,849.95. Following the transaction, the senior vice president now owns 14,856 shares in the company, valued at $922,706.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Bradley J. Tandy sold 2,491 shares of the business’s stock in a transaction on Monday, February 27th. The shares were sold at an average price of $56.08, for a total transaction of $139,695.28. Following the completion of the sale, the senior vice president now directly owns 13,483 shares of the company’s stock, valued at $756,126.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patricia A. Lang sold 545 shares of the company’s stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $62.11, for a total transaction of $33,849.95. Following the completion of the sale, the senior vice president now directly owns 14,856 shares of the company’s stock, valued at $922,706.16. The disclosure for this sale can be found here. Insiders have sold 65,881 shares of company stock worth $3,738,005 over the last quarter. Insiders own 5.10% of the company’s stock.
Analyst Upgrades and Downgrades
Enovis Trading Down 0.5 %
ENOV stock opened at $54.81 on Friday. The company has a quick ratio of 1.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.08. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $68.15. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -57.09 and a beta of 2.01. The firm’s fifty day simple moving average is $54.76 and its two-hundred day simple moving average is $56.26.
Enovis (NYSE:ENOV – Get Rating) last posted its quarterly earnings data on Thursday, May 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Enovis had a negative net margin of 3.24% and a positive return on equity of 3.70%. The business had revenue of $406.20 million for the quarter, compared to analysts’ expectations of $389.95 million. During the same quarter in the previous year, the business posted $0.37 earnings per share. The business’s revenue was up 8.2% compared to the same quarter last year. As a group, analysts anticipate that Enovis Co. will post 2.27 earnings per share for the current year.
Enovis Company Profile
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV – Get Rating).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.